

CURRICULUM VITAE
Cynthia Louise Comella, M.D.

Citizenship: United States of America

Contact Information:

Department of Neurological Sciences
Section of Parkinson's Disease and Movement Disorders
Rush University Medical Center
1725 W. Harrison Street, Suite 755
Chicago, IL 60612
Telephone: (312) 563-2900 Fax: (312) 563-2024
Email: Cynthia_L_Comella@rush.edu

EDUCATION:

1976-1980 M.D.
University of Cincinnati Medical College
University of Cincinnati
Cincinnati, OH

1972-1976 B.A. (Biochemistry)
Cum Laude, Phi Beta Kappa
Smith College
Northampton, MA

INTERNSHIP, RESIDENCY AND FELLOWSHIP:

- 1980-1983: 3-Year Residency in Internal Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL
- 1983-1984: Neurology Residency - First year, Rush-Presbyterian-St. Luke's Medical Center Chicago, IL
- 1985-1987: Neurology Residency, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL
- 1987-1989: Fellowship - Movement Disorders Center, Rush-Presbyterian-St. Luke's Hospital Chicago, IL
- 1988-1989: Pillsbury Fellowship, Rush-Presbyterian-St. Luke's Medical Center Chicago, IL
- 1992-1995 Fellowship: Sleep Disorder. Sleep Disorders Center. Rosalind Cartwright, Ph.D. (Director) Rush-Presbyterian St. Luke's Medical Center, Chicago, IL

CERTIFICATION and LICENSURE

1987 Board Eligible: Internal Medicine
1988 Board certified - American Board of Neurology and Psychiatry
1996 Diplomat - American Board of Sleep Medicine

Medical License: Illinois 036-067144 Expires 7/31/2012

ACADEMIC APPOINTMENTS:

2005-present: Professor, Department of Neurological Sciences, Rush University Medical Center
Chicago, IL
1995-2005: Associate Professor, Department of Neurologic Sciences, Rush University
Medical Center, Chicago, IL
1980-present: Instructor, Department of Internal Medicine, Rush University Medical Center,
Chicago, IL
1993-1997: Assistant Professor, Department of Psychology and Social Sciences, Rush
University Medical Center, Chicago, IL
1989-1994: Assistant Professor, Movement Disorders Section, Department of Neurological
Sciences, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL
1985-1995 Instructor, Alternative Curriculum, Rush Medical College, Chicago, IL
1983-1989: Instructor, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's
Medical Center, Chicago, IL
1983-1985 Instructor, Allied Health Department, Chicago State University, Chicago, IL

EMPLOYMENT:

1989-present: Attending, Department of Neurological Sciences, Rush University Medical Center
Chicago, IL
1980-present: Instructor, Department of Internal Medicine, Rush University Medical Center,
Chicago, IL
1993-1997: Assistant Professor, Department of Psychology and Social Sciences, Rush
University Medical Center, Chicago, IL
1985-1996 Instructor, Alternative Curriculum, Rush Medical College, Chicago, IL
1983-1989: Instructor, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's
Medical Center, Chicago, IL
1983-1986 Instructor, Allied Health Department, Chicago State University, Chicago, IL

UNIVERSITY COMMITTEES:

1992-Present: Advisory Committee for Neurological Sciences
1991-1998: Department of Neurological Sciences Education Committee
1990-1993: Chairman: Department of Neurological Sciences Grand Rounds Program
1990-1998: Department of Neurological Sciences Library
1993-1997: Rush Medical Center: University Committee on Research

MEDICAL SOCIETIES AND STUDY GROUPS

AMERICAN ACADEMY OF NEUROLOGY

Committees

2002, 2003 Mentorship Program

Therapeutics Assessment Committee: Botulinum Toxins

1997, 2005 Member: Topic Chair: Cervical Dystonia

Movement Disorders Section

1997-2001 Executive Committee At-large Member

2001-2003 Executive Committee Secretary

2003-Present Executive Committee: MDS Education Committee Liaison

Sleep Section

1999-2000 Executive Committee At-large Member

2000-2002 Executive Committee Secretary

2002-2004 Executive Committee Chair-elect

2004-2007 Chair, Executive Committee

2006 Committee on Sections

Standing Committees and Subcommittees

1999,2003 Scientific Sessions Subcommittee: Movement Disorders Reviewer

2000-2003 Scientific Sessions Subcommittee: Movement Disorders Program Chairman

2003-present Science Committee Member

2003-present Continuum Editorial Board Committee

1999-Present Botulinum Toxins Workshop Advisory Committee

1999-2003 Chairman

2003-Present Member

2003-2005 Movement Disorders Research Awards Committee

2005-2007 Chairman, Movement Disorders Research Awards Committee

2006 Member: Patient Safety Subcommittee

American Academy of Neurology: Annual Meeting Activities

- 1990 American Academy of Neurology
Platform Presentation: Dysphagia Following Botulinum Toxin Injections for Spasmodic Torticollis.
- 1991 American Academy of Neurology
Platform Presentation: The Role of Electromyography in Botulinum Toxin Injections for Spasmodic Torticollis.
- 1993-1995 Faculty: American Academy of Neurology, New York, NY: Advanced Usefulness of Botulinum Toxin for Dystonia; Workshop on the Botulinum Toxins Treatment for Focal Dystonia.
- 1994 American Academy of Neurology Meeting, Washington, DC.
Course Director: Advanced Usefulness of Botulinum Toxin.
Faculty: Botulinum Toxin: A Workshop. Mitchell Brin, M.D. (director).
American Academy of Neurology
- 1995 American Academy of Neurology, Seattle, Washington
Faculty: Tourettes Syndrome. Neurochemistry and treatment. Roger Kurlan, M.D. (director).
Faculty: Botulinum Toxin Clinical Skills Workshop. Mitchell Brin (director).

- 1996 Platform Presentation: Sleep Benefit in Parkinson's Disease.
 Session Chairman: Movement Disorders: New Therapies
 Faculty: Movement Disorder Highlights (Christopher G. Goetz, M.D., Director)
 Co-Director: Botulinum Toxin Workshop (Mitchell Brin, M.D., Co-Director)
 Faculty: Gilles de la Tourette Syndrome (Peter Como, Ph.D., Chair)
 Faculty: Practical Management of Movement Disorders (Caroline Tanner, M.D., Director)
 Faculty: Identification of Common Movement Disorders
 Poster Presentation: Specific Dystonic Factors Contributing to Disability in Cervical Dystonia.
- 1997 Session Chairman: Sleep and Movement Disorders
 Course Director: Clinical Usefulness of Botulinum Toxin Workshop
 Course Director: Sleep Disturbances in Parkinson's Disease
 Faculty: Tourettes Syndrome, Dinner Seminar (Peter Como, Ph.D., Director)
 Faculty: Practical Management of Movement Disorders (Caroline Tanner, M.D., Ph.D., Director)
- 1998 American Academy of Neurology Meeting, San Diego
 Session Chairman: Sleep and Movement Disorders
 Director: Clinical Skills Workshop: Botulinum Toxin for Dystonia and Other Disorders
 Faculty: Tourette Syndrome (Peter Como, Ph.D., Director)
 Faculty: Practical Management of Movement Disorders: Sleep Problems (Caroline M. Tanner, M.D., Director)
 Platform Presentation: Reliability of the Unified Dystonia Rating Scale
- 1999 American Academy of Neurology, Toronto, ON
 Session Chair: Therapeutics in Parkinson's disease
 Platform presentation: The Reliability and Validity of the Unified Dystonia Rating Scale
 Presenter: Movement Disorders Highlights
 Director: Botulinum Toxin Skills Workshop
 Faculty: Sleep and Movement Disorders (Director-Wayne Hening)
 Faculty: Practical Management of Movement Disorders (Director-Caroline Tanner)
- 2000 American Academy of Neurology Annual Meeting, San Diego, CA
 Co-Director: Movement Disorder Highlights
 Course Director: Botulinum Toxin Skills Workshop
 Faculty: Practical Management of Movement Disorders (Director: Caroline Tanner, M.D.)
 Faculty: Practical Management of Dystonia (Director: Susan Bressman, M.D.)
- 2001 American Academy of Neurology Annual Meeting, Philadelphia, PA
 Course Director: Sleep Disturbances in Parkinson's Disease
 Course Director: Botulinum Toxins Skills Workshop
 Faculty: Diagnosis and Treatment of Dystonia (Susan Bressman, M.D., Director)
- 2002 American Academy of Neurology Meeting, Denver, CO
 Session Chair: Parkinson's Disease Pathophysiology
 Director: Sleep Disturbances in Parkinson's Disease

- 2003 Faculty: Movement Disorders Course (William Weiner, M.D., Director)
 Faculty: Management of Dystonia (Susan Bressman, M.D., Director)
 Faculty: Botulinum Toxins Skills Workshop
 American Academy of Neurology, Honolulu, Hawaii
 Course Director: Sleep Disturbances in Parkinson's Disease
 Organizer: Young Investigator Lunch with the Experts
 Session Chair: Epidemiology of Movement Disorders
 Faculty: Practical Management of Movement Disorders (Susan Bressman, M.D., Director)
 Faculty: Botulinum Toxins in Movement Disorders (Charles Adler, M.D., Director)
- 2004 Faculty: The Neurology of Sleep Disorders (Antonia Culebras, M.D., Director)
 American Academy of Neurology, San Francisco, CA
 Course Director: Movement disorders in sleep
 Faculty: Botulinum toxins for dystonia (C. Adler, Director)
 Faculty: Botulinum toxins: Clinical workshop (A. Brashear, Director)
 Faculty: Practical Management of Parkinson's disease (S. Bressman, Director)
 Session Chair: Parkinson's disease
- 2005 American Academy of Neurology, Miami, FL
 Course Director: Practical management of Parkinson disease
 Faculty: Treatment of advanced Parkinson disease
 Faculty: Botulinum toxins skills workshop
- 2006 American Academy of Neurology, San Diego, CA
 Platform Presentation: Botulinum Toxins and dysphasia.
 Poster Presentation: RLS in Parkinson Disease
 Educational Courses:
 Faculty: Movement Disorders (Kathleen Shannon, Director)
 Faculty: Botulinum Toxin Workshop (Charles Adler, Director)
 Faculty: Practical Management of Movement Disorders (Susan Bressman, Director)
 Faculty: Update on Movement Disorders (Mark Hallett, Director)
 Organizer: Integrated Neuroscience Program
 Program: Genetics in Movement Disorders

MOVEMENT DISORDERS SOCIETY

- 1991-Present Member
- 2002-2005 International Executive Committee
- 2000-2003 Chairman: Botulinum Toxins Skills Workshops Advisory Committee
 (Collaborative AAN/MDS Programs)
- 2003-Present Member: Botulinum Toxins Skills Workshops Advisory Committee
 (Collaborative AAN/MDS Programs) (Allison Brashear, Chairman)
- 2002-Present Chairman, Education Committee
 ACCME Accreditation Committee
 Course Planning: 2003-2004
 Peter Moore
 Evidence Based Medicine Review

- Motor Fluctuations in Parkinson's disease
 Visiting Professor Program
 Botulinum Toxins Skills Workshop
- 2003-Present Member: Industrial Relations Committee (Olivier Rascol, Chairman)
 2003-Present Member: International Congress Science Committee
 2002-2006 International Congress of Movement Disorders. New York, NY
 Faculty: Treatment of Dystonia. New York, NY
 Faculty: Sleep in Parkinson's Disease. New York, NY
- 2006 Member: Congress Planning Committee
 2006 Reviewer: Congress Abstracts
 Kyoto, Japan
- 2006 Ad Hoc: Continuing Medical Education Committee

PARKINSON STUDY GROUP

- 1991-Present Member
 1996-Present Co-principal investigator: PRIME study (Caroline Tanner, M.D., Ph.D., Principal investigator)
 Minority and Gender Task Force, 1996-2001
 Workshop: Minorities in Clinical Trials, 1996
 Chairman: Nominating Committee, 1997-1998
- 2002 Chairman, Organizing committee.
 Sixteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and Movement Disorder Society. *Movement Disorders* 2002; 12(5):833-847.
- 2002-2004 Chairman, Organizing committee.
 Sixteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and Movement Disorder Society. *Movement Disorders* 2003; 12(5):833-847.
- 2002-2006 PSG Executive Committee member.

DYSTONIA STUDY GROUP

- 1997 Co-Founder Dystonia Study Group
 1997-Present Chairman, Executive Committee

CHICAGO NEUROLOGIC SOCIETY

- 1995-Present Member
 1998-1999 Secretary/Treasurer
 1999-2000 Vice President
 2000-2001 President

CHICAGO NEUROLOGICAL SOCIETY ACTIVITIES

- 1991 Botulinum Toxin and the Treatment of Dystonia
 2000 Parkinson's Disease: Treatments

AMERICAN NEUROLOGICAL ASSOCIATION

- 1997 Elected to membership.
2003 Plenary lecturer: Restless Leg Syndrome, REM Behavioral Disorder, and Parasomnias.
Sleep: Scientific Foundations and Clinical Disorders.

ACADEMY OF SLEEP MEDICINE :

- 1997- present Member
2001 Faculty: Restless Legs and Sleep Disturbances in Parkinson's Disease.
American Academy of Sleep Medicine: Annual Meeting
2002 Faculty: Movement Disorders and Sleep
American Academy of Sleep Medicine: Annual Meeting
Chicago, IL
2006 APSS meeting, Salt Lake City, Utah
Faculty: Parkinson disease for sleep specialist
Course Director: Michael Thorpy
Faculty: REM behavior disorder:
Course Director: Jacques Montplaisir

AMERICAN ACADEMY OF SLEEP MEDICINE

- 1997-present Member

NATIONAL EASTER SEALS SOCIETY:

- 1997 Course Director: National Easter Seal Society Workshop: Treatment Options for Spasticity
Chicago, IL
1998-2001 Director: Educational Programs for Treatment of Spasticity

WE MOVE ORGANIZATION:

- Judith Blazer, M.S., Executive Director
Physician Advisory Board: 1996-1999
CME Advisory Board: 1999-2001
Education Committee: 2005-present

DYSTONIA MEDICAL RESEARCH FOUNDATION

- 2000-2003 Scientific Advisory Board

EDITORIAL EXPERIENCE:

- Clinical Neuropharmacology:
Editorial Board: 1995-2003
Sleep Section Editor: 1995-present
Sleep Medicine:
Editorial Board: 2006-present
Movement Disorders Journal:
Editorial Board: 1997-2001
Reviewer

Neurology:

Ad Hoc Reviewer

Journal of Neurology:

Ad Hoc Reviewer

Annals of Neurology

Ad Hoc Reviewer

Muscle and Nerve

Ad Hoc Reviewer

Journal of Neurology, Neurosurgery and Psychiatry

Ad Hoc reviewer

Brain

Ad Hoc reviewer

SELECTED ACADEMIC PRESENTATIONS

1991

Faculty: *Pathophysiology of Basal Ganglia Disorders*, Cologne, Germany

1992

Faculty: *Treatment of Advanced Parkinson's Disease*,
Ohio State University, Columbus, Ohio
St. Elizabeth's Hospital, Dayton Ohio
Jewish Hospital, Cincinnati, Ohio

Faculty: *Use of Botulinum Toxin in Cervical Dystonia*. American Academy of Neurology,
San Diego. Course Director: Mitchell Brin, M.D.

Co-chairman: International Dystonia Symposium. Chicago, IL. Co-chairman and meeting
organizer. Presentation: Botulinum Toxin treatment for focal dystonia.

1993

Course Director: The use of botulinum toxin for the treatment of focal dystonia:
Rush-Presbyterian-St. Luke's Medical Center.

Faculty: American Academy of Neurology: Treatment of dystonia.
Joseph Jankovic, Course director, Houston, TX.

Course Director: American Academy of Neurology: Treatment of dystonia. Chicago, IL.

Faculty: Movement Disorders: A Review Course for Residents
University of Kansas
Chicago, Houston, Philadelphia, Baltimore, Miami, New York.

1994

Faculty: International Dystonia Symposium, Houston, TX

Faculty: Treatment of Parkinson's Disease, Keystone, CO

1995

Parkinson Study Group Symposium. The Treatment for Truncal Dystonia with Botulinum Toxin. San Francisco, CA

The Toronto Western Spasmodic Torticollis Teaching Tape: Parkinson Study Group Symposium. Washington DC

Disorders of the Basal Ganglia. Sports, Dance Movement and the Brain: A symposium. The Foundation for Human Potential. Art Institute of Chicago.

Session Chairman: Conference on Botulinum toxin, Munich, Germany

1996

Treatment of Gilles de la Tourette's syndrome: Clinical Features and treatment of Tardive Dyskinesia, William Weiner M.D., Director
University of Miami, Miami FL

Invited Lecturer: Parkinson's disease, Update in Neurology for the Primary Care Physician
American Academy of Family Physicians, Annual meeting,
Chicago, IL

Director and Organizer: Parkinson Disease: Update for Neurologist and Primary Care Physicians, Rush Medical College
Chicago, IL

International Dystonia Symposium
San Francisco, CA

American Society of Neurorehabilitation, Treatment of Spasticity with Botulinum Toxin
Christopher O'Brien, Director

National Center for Medical Education: Biologic Basis of Neurology and Psychiatry
Movement Disorders, Identification and Treatment
Cook County Hospital, Chicago, IL

Sleep Disorders Center: Grand Rounds: Sleep Disorders in Multiple System Atrophy
Chicago, IL

Wisconsin Neurologic Association, Botulinum Toxin Usefulness

Pathophysiology and Treatment of Dystonia, Department of Neurology Grand Rounds
University of Calgary, Canada

Botulinum Toxins and Dystonia, Neurology Grand Rounds, Ohio State University
Columbus, OH

1997

Botulinum Toxin for the Treatment of Pain. Allergan Advisory Board
Aspen, CO; Dallas, TX; Phoenix, AZ

Course Organizer and Director: Parkinson's Disease: Treatment with "Old and
New" Medicines, Rush Medical College
Chicago, IL

1998

Director: Management of Chronic Pain, Including Usefulness of Botulinum Toxin
Discovery International, Chicago, IL

Treatment of Parkinson's Disease, Neurology Grand Rounds
Christ Hospital, Oak Lawn, IL

Medical Advisor: FDA Panel for Approval of BOTOX for Cervical Dystonia
Washington, DC

Symposium and Advisory Board: Blepharospasm Study of BOTOX
Phoenix, AZ

Chairman: Treatment of Myofascial Pain
Discovery International, Chicago, IL

Presentation and Advisory Panel
Allergan Pharmaceuticals, Orlando, FL

Treatment of Parkinson's Disease, Internal Medicine Grand Rounds
Christ Hospital, Oak Lawn, IL

1999

Faculty: Symposium on Movement Disorders, University of Kansas, William Koller, M.D.,
Ph.D., Chairman
Denver, CO

Faculty: Treatment of Parkinson's Disease, Munson Medical Center,
Traverse City, MI

Treatment of Parkinson's Disease, Neurology Grand Rounds
University of Michigan, Ann Arbor, MI

Invited Lecturer: Sleep in Parkinson's Disease.
Parkinson's Institute, Sunnyvale, CA

Invited Lecturer: Treatment of Dystonia, MAO Clinic Annual Neurology Course
Las Vegas, Nevada

Faculty: Identification of Common Movement Disorder, Neurology for the Non-Neurologist
Rush Medical College, Chicago, IL

2000

Treatment of Parkinson's Disease: Update, Department of Medicine Grand Rounds, Oak
Park Hospital, Oak Park, IL

Sleep in Parkinson's Disease, Grand Rounds, Northwestern University
Chicago, IL

Parkinson's Disease: Sleep Disorders, APDA visiting Professor
Orange County, CA

Restless Legs Syndrome: New concepts in treatment, Chicago Neurological Society
Chicago, IL

Dystonia: Update on treatment, Department of Neurological Sciences Grand Rounds
Rush Presbyterian St. Lukes Medical Center
Chicago, IL

Clinical Trials in a Multi-center Environment, Bachman Strauss Dystonia Foundation Annual
Symposium
New York, NY

Faculty: Physician Symposium on Parkinson's Disease
Appleton, WI

Faculty: Movement Disorders Review, University of Illinois
Chicago, IL

Dystonia: Update on Genetics and Treatment, Department of Neurology, Grand Rounds
Yale University

Focal Dystonia: clinical features and management, Department of Neurology, Grand Rounds,
University of Oregon
Portland, OR

Sleep in Parkinson's Disease, Department of Psychology: Sleep Disorders Center, Grand
Rounds, Rush Presbyterian St. Lukes Medical Center
Chicago, IL

Botulinum Toxins in Clinical Practice, Department of Neurology, Grand Rounds, University of Wisconsin
Milwaukee, WI

2001

Dystonia: New Genes, New Treatments, Grand Rounds: Department of Neurological Sciences, Yale University
New Haven, CT

Clinical Trials for Dystonia, Grand Rounds, Department of Neurology, University of Rochester
Rochester, NY

Botulinum Toxin Regional Workshop, American Academy of Neurology
New York, NY

Caribbean Movement Disorders review Course, Faculty, Emory University
Bahamas

Clinical Features and Genetics of Dystonia, Department of Neurology: Grand Rounds, University of Indiana
Indianapolis, IN

Botulinum Toxins in Clinical Practice, Department of Internal Medicine: Grand Rounds, University of Arizona
Tucson, AZ

Differential Diagnosis of Parkinsonism, Department of Neurological Sciences: Grand Rounds, University of Chicago
Chicago, IL

Treatment of Parkinson's Disease, Department of Internal Medicine: Grand Rounds
Melrose Park, IL

Movement disorders Review Course: Regional Symposia, Faculty: Dystonia Sleep in Parkinson's Disease, Restless Leg Syndrome, Sponsored by Emory University
Locations: Pittsburgh, PA
Miami, FL
San Diego, CA
Washington D.C.
San Francisco, CA
New York, NY

2002

Sleep Disorders in Parkinson's Disease, Visiting Professor, Department of Neurological Sciences, University of Michigan

Ann Arbor, MI

Faculty: Botulinum Toxins Regional Workshop, American Academy of Neurology
Washington D.C.

Plenary Presentation: Development of Clinical Trials for Dystonia, International Congress on
Botulinum Toxins
Hannover, Germany

Plenary Sessions: Rating Scales for Dystonia, International Dystonia Symposium
New York, NY

Director: Advanced Clinical Skills Workshop: Botulinum Toxins, American Academy of
Neurology
Chicago, IL

Co-Chair: Botulinum Toxins for Dystonia and Spasticity
Houston, Texas

Movement Disorders: An Update and Case Presentations, Regional Symposia, Emory
University
San Antonio, TX
Cincinnati, OH
Washington, DC
Tampa, FL
New Orleans, LA
San Francisco, CA

2003

Movement Disorders: An Update and Case Presentations, Regional Symposia, Emory
University
St. Louis, MO
Atlanta, GA
Seattle, WA
Minneapolis, MN
New York, NY

Botulinum Toxins Skills Workshop, American Academy of Neurology: Regional Programs,
Milwaukee, WI

Organizer: Restless Legs: Experts Workshop, Co-Chair: Claudia Trenkwalder
Chicago, IL

Faculty: Motor Fluctuations, Progress and Possibilities in Parkinson's Disease, Struther's
Parkinson Center, Chair: Martha Nance, M.D.

Co-Organizer and Co-Chairman, Treatment of Parkinson's Disease, Rush University Medical Center
Chicago, IL

Faculty: Sleep in Parkinson's Disease, Dystonia, Restless Legs Syndrome, Caribbean Movement Disorders Review Course, Emory University
Caymen Islands, BI

Faculty: Awake and Involved: Addressing Excessive Daytime Sleepiness in Patients with Parkinson's Disease, Projects in Knowledge
Chicago, Cincinnati, Cleveland

Presenter/Discussant: Speech Disorders Related to Movement Disorders, Lana Shekeim, M.D., Director, NIDCD Workshop
Bethesda, MD

Faculty: Sleep Disorders in Parkinson's Disease, Symposium on Parkinson's Disease
Chairman: Dee Silver, M.D.
San Diego, CA

2004

Parkinson Disease, Visiting Professor
University of California at Irvine

Parkinson Disease and Sleep disorders, Visiting Professor
Medical University of South Carolina

Movement Disorders Review Course, Emory University
Chicago, Charlotte, Saint Louis

Motor fluctuations in Parkinson's disease, Movement Disorders Review Course, Joseph Jankovic, Director
Houston TX, Chicago IL, Los Angeles CA.

2005

Movement disorders Review Course, Faculty: Sleep disorders in Parkinson's disease, dystonia, Treatment of RLS, Director: Ray Watts, William Koller, University of Alabama
St. John's, Virgin Island

Case presentations in Movement disorders, Faculty, Christopher Goetz, director, Rush University Medical Center

Movement disorders Review course, Faculty, Ray Watts, William Koller: director, University of Alabama
Phoenix. AZ

9th International Congress of Parkinson Disease and Movement Disorders, Seminar faculty:
RLS: epidemiology and disease burden, Seminar faculty: Excessive daytime
sleepiness in Parkinson disease, Chair: Botulinum toxin for movement disorders,
Faculty: Clinical overview of dystonia
New Orleans, LA

American Academy of Neurology, Course Director: Practical Management of Parkinson's
disease, Faculty: Treatment of Advanced PD
Miami, FL

Grand Rounds, Beth Israel Medical Center, Department of Neurological Sciences, Sleep
disorders in Parkinson disease

Grand Rounds, Case Western Reserve, Department of Neurology, Nighttime sleep and
Parkinson disease

16th International Congress on Parkinson disease, Presenter: Sleep and behavior in Parkinson
disease, Presenter: Use of dystonia scales in clinical practice
Berlin, Germany

Symposium on Parkinson disease, Presenter: RLS: Clinical features and pathophysiology
Montreal, Canada

10th International Symposium on the treatment of Parkinson disease, Yoshi Mizuno, Chair
Faculty: Sleep disturbances in Parkinson disease
Kobe, Japan

2006

Canadian International Botulinum Toxins Symposium, Faculty
Toronto, Canada

Movement Disorders Review Course,
University of Alabama
San Diego
Denver
Philadelphia

Michael J. Fox, Cleveland Discovery Giant Proposal, Reviewer

World Parkinson Congress, Infectious causes of parkinsonism, Sleep disturbances in
Parkinson's disease
Washington, DC

Prime Med Updates on RLS
Chicago

Oak Brook
Indianapolis
Virginia

Northwestern University, Parkinson disease Symposium, Faculty

American Psychiatry Association, Diagnosis of RLS, Faculty
Toronto, Canada

American Academy of Neurology, Platform Presentation

Japanese Neurological Society, Botulinum Toxins, Faculty
Tokyo, Japan

1st International Meeting on Parkinson's Disease, Faculty, Mitsutoshi Yamamoto, Course
Director
Tokyo, Japan

American Academy of Sleep Medicine, Faculty: Neurology on Sleeping (Michael Thorpy,
Director), Faculty: REM Behavior Disorder Discussion Group, (Carlos Schenck,
Director)

Neurology Grand Rounds, University of Chicago, Dystonia

Michigan PD Patient Support Group

Young onset Parkinson Disease Conference
Norton, Virginia

2007

February, 2007: Faculty, Cornell University Update Symposium
Tel Aviv, Israel

March, 2007: Visiting Professor, University of Alabama, Department of Neurology

April, 2007: American Academy of Neurology presentations, Director, presenter: Botulinum
toxins in neurological disease

Faculty: Botulinum toxin workshop, Director: Allison Brashear

Faculty: Sleep and hallucinations in Parkinson's disease, Director: Nico Diederich

May, 2007: Visiting Professor: Neurology, Fleni Institute
Buenos Aires, Argentina

June, 2007: International Congress, Istanbul, Movement Disorders Society, Director, presenter: Sleep disorders course; Chair: Botulinum toxins

Grand Rounds: Parkinson's disease, Psychiatry grand rounds, Rush Medical Center

June, October 2007: Member: Cure Dystonia Initiative, Dystonia Medical Research foundation

2007: CME programs:

Prime-med programs: Chicago, St. Louis, Los Angeles, New York

Paths program: Cleveland, St. Louis

University of Alabama Movement Disorders Review Course

Movement Disorders Society

Restless legs syndrome and Parkinson disease (San Francisco)

Many Faces of Dystonia: New York, Chicago, San Francisco

2007: New committee appointments: (In addition to those already in CV)

American Academy of Neurology:

Executive committee of the Committee on Sections

Movement Disorders Society:

Congress Scientific Planning Committee

International Congress Oversight Committee

International Congress local planning committee

CLINICAL RESEARCH

NIH funding

NIH Grant No.: FD-R-001043-02.

7/01/94-7/01/97

PSYCLOPS Friedman J

Psychosis and Clozapine in Parkinson's Disease (PSYCLOPS)

FDA Orphan Drug Research Program.

Role: Site investigator

PHAROS Shoulson

6/01/99 - 10/31/07

Huntington Study Group

Prospective Huntington at Risk Observational Study (PHAROS)

This is an observational study of subjects at risk for Huntington's disease.

Role: Sub-Investigator/Site Blinded Rater

5 R01 NS 34796 (Fahn)

1/1/2000-12/31/2001

NIH

Early vs. Late L-Dopa in Parkinson's Disease (the ELLDOPA Study)

The primary objective of this trial is to determine whether or not chronic administration of levodopa to early otherwise untreated PD patients will result in a significant worsening of their

disease, as assessed by the Unified Parkinson's disease Rating Scale (UPDRS) 2 years after randomization and 14 days after withdrawal of all medications.

Role: Sub-investigator/Site Primary Rater

Protocol No. 1 U10 NS44475-01(Shannon)

9/30/02-8/31/07

NIH/NINDS

Parkinson's Disease Neuroprotection Clinical Trial: Clinical Center

This trial embodies a two pilot studies intended to inform the drug selection and outcome measures for a subsequent larger longer trial of agents intended to modify the course of PD progression.

Role: Sub-Investigator

2 R01 NS28127 -10 (Corcos)

3/1/1995-2/28/2005

NIH

Motor Deficits – Experimental and Clinical Coordinates

The purpose of this study is to learn more about Parkinson's disease through clinical examination and motor control testing.

Role: Site principal investigator

2 R01 NS36630-05 (Marder)

7/1/2004-6/30/2009

NIH

Genetic Epidemiology of Parkinson's Disease

The purpose of this study is to determine whether there is a parkin carrier phenotype characterized by psychiatric and/or cognitive impairment prior to the onset of motor signs that defines PD and to determination of age specific penetrance of parkin mutations, and the examination of how penetrance differs by allelotype.

Role: Site Principal Investigator

Investigator initiated/ internal funding:

University Committee on Research, "Quantitative sleep studies in chronically treated Parkinson's disease patients with sleep disruption and hallucinations", C. Comella (Principal Investigator). 1993-1995

Department of Neurological Sciences Research grant: Propranolol for the treatment of akathisia in Parkinson's disease". C. Comella, M.D. (Principal Investigator) 1993-1995

University Committee on Research, "Determining a dose-effect curve for botulinum toxin in spasmodic torticollis". A. Buchman, C. Comella, G. Stebbins.

Investigator initiated/ external funding

Allergan Pharmaceutical. Quality of Life measures in cervical dystonia before and following botulinum toxin treatment. Educational grant. Cynthia L. Comella (Principal Investigator).

Tourette Syndrome Association, Pimozide-free summer vacations in school aged GTS patients. Cynthia L. Comella (Principal Investigator).

Tourette Syndrome Association. Memory Systems analysis in adults with Tourette Syndrome. Glenn T. Stebbins (Principal investigator), Cynthia L. Comella, John Gabrieli (Co-investigators).

Elan Pharmaceutical 2/20/2000-2/19/2005
A Double-Blind, Placebo-Controlled, Randomized Pilot Clinical Study to Assess the Tolerability of Add-On Night-Time Therapy with Permax (Pergolide Mesylate) for Sleep Disturbances in Patients with Parkinson's Disease
Role: Principal investigator

**Industry sponsored
Current**

1198.100 6/2003-5/2005
Boehringer-Ingelheim Pharmaceuticals NS 2330 / SCEPTRE
Role: Site Principal Investigator

P02541 6/2003-5/2005
Schering-Plough Phase 2 Double-Blind, Dose-Finding, Placebo-Controlled Study to Assess the Efficacy and Safety of SCH 420814 as Monotherapy in Subjects with Early Parkinson's Disease.
Role: Site Principal Investigator

Botulinum Toxin Type B Observational Study (BOS) 8/31/2001-8/30/2005
Multicenter Clinical Assessment. Joseph Jankovic: Principal Investigator
Role: Site Principal Investigator

Botulinum Toxin Type B Observational Study (BOS) 8/31/2001-8/30/2005
Multicenter Clinical Assessment. Joseph Jankovic: Principal Investigator
Role: Site Principal Investigator

191622-017-00 3/30/2001-12/31/2005
Allergan, Inc. Observational Study of BOTOX® Use in Cervical Dystonia
Role: Site Principal Investigator

AN072-401CD/North American 5/2001-12/2006
Elan Pharmaceuticals
An Open Label Safety and Immunogenicity Study of Myobloc™ (Neurobloc®; Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia.
Role: Site Principal Investigator

Y-47-52120-706 11/2002-12/31/2004
Ispen
Phase II, Multi-Center, Randomized Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Administration by Subcutaneous Injection of 3 doses

of Dysport (40 units/eye, 80 units/eye, and 120 units/eye) for the Treatment of Benign Essential Blepharospasm

Role: Site Principal Investigator

Completed

Boehringer Pharmaceutical Company, "Efficacy of SND-919 for the treatment of advanced Parkinson's disease". Cynthia L. Comella (Principal Investigator).

Allergan Pharmaceuticals. A double masked, vehicle-controlled evaluation of the safety and efficacy of intramuscular botulinum toxin type A (Oculinum) for the treatment of essential tremor. Cynthia Comella (Principal investigator).

Allergan Pharmaceutical. Antibody formation following Botulinum toxin injection for Cervical Dystonia. Cynthia Comella (Principal investigator).

Boehringer Pharmaceutical Company, "Efficacy of SND-919 for the treatment of advanced Parkinson's disease" Phase 3. Cynthia L. Comella (Principal Investigator).

Eli Lilly. Differential Effect of pergolide and parlodel on cognition and affect in Parkinson's Disease. Cynthia L. Comella (Principal investigator).

Hoffman La Roche. Tolcapone in treated Parkinson Disease. Cynthia Comella, (Principal Investigator).

Athena Neuroscience. A Double-Blind, Placebo-Controlled, Single Dose Safety and Efficacy Study of Botulinum Toxin Type B in Patients with Cervical Dystonia. Cynthia L. Comella (Principal Investigator)

Athena Neuroscience. A Double-Blind Placebo Controlled Single Dose Safety and Efficacy Study of Botox B in Type-A Resistant Patients with Cervical Dystonia, Cynthia L. Comella (Principal Investigator).

Athena Neuroscience. An Open-Label, Safety Study of Neurobloc (botulinum toxin type B) in patients with cervical dystonia, Cynthia L. Comella (Principal Investigator).

Hoffman-LaRoche. Evaluation of the Efficacy and Safety of Tolcapone in Parkinson's Disease Patients with Stable Response to Carbidopa/Levodopa, Cynthia L. Comella (Site Principal Investigator)

Boehringer-Ingelheim. Double-Blind, Placebo Controlled Parallel Group Comparison to Assess the Safety, Tolerance and Efficacy of Pramipexole in Advanced Parkinson's Disease and to Assess long-Term Safety with Open-Label Pramipexole. Cynthia L. Comella, M.D. (Site Principal Investigator).

Hoffmann-LaRoche. Open-Label, Randomized Parallel Group Comparison of Tolcapone and Pergolide Given in Combination with Carbidopa/Levodopa in Parkinsonian Patients Who Exhibit End of Dose “Wearing Off”, with Follow-Up Extension of Tolcapone. Cynthia L. Comella, M.D. (Site Principal Investigator).

Hoffmann-LaRoche. A Long-Term, Double-Blind Comparison Study of Tolcapone Versus Placebo Given in Combination with Levodopa/AADC1 in Delaying the Onset of Motor Fluctuations in Parkinson’s Disease Patients Native to Levodopa Therapy, Cynthia L. Comella, M.D. (Site: Principal Investigator)

Amgen, Medtronic. Randomized, Double-Blind Placebo Controlled Dose Escalation Trial of Intracerebroventricular Recombinant-Methionyl Human Glial Cell Line Derived Neurotrophic C Factor for the Treatment of Patients with Idiopathic Parkinson’s Disease, Cynthia L. Comella, M.D. (Site: Principal Investigator).

Amgen, Medtronic. An Extension to an Open Label Trial of r-methGDNF for the treatment of Patients with Idiopathic Parkinson’s Disease, Cynthia L. Comella, M.D (Site: Principal Investigator)

Amgen, Medtronic. Open-Label, Within Patient, Dose Escalation Trial of Intracerebroventricular Recombinant Methionyl and Glial Cell Line Derived Neurotrophic Factor for the Treatment of Patients with Idiopathic Parkinson’s Disease, Cynthia L. Comella, M.D. (Site Principal Investigator).

Ipsen. A phase III multicenter prospective randomized, double-blind, placebo-controlled study of the efficacy and safety of Dysport for the treatment of cervical dystonia (Cynthia Comella, M.D., site principal investigator).

Allergan Pharmaceuticals: A Multicenter, Double-Blind Placebo Controlled Parallel Dose Response Clinical Trial of BOTOX Purified Neurotoxin Complex for the Treatment of Upper Limb Spasticity in Post-Stroke Patients, Cynthia L. Comella, M.D. (Site: Principal Investigator)

Allergan Pharmaceutical: A Randomized, Multicenter, Double-Blind Parallel Clinical Trial to Compare the Safety and Efficacy of BOTOX Purified Neurotoxin Complex Manufactured from Campbell Neurotoxin Complex Lot 1 to that Manufactured from Neurotoxin Complex Lot 79-11 in Blepharospasm Patients, Cynthia L. Comella, M.D. (Site: Principal Investigator)

Allergan. An Open-Label, Multicenter, Clinical Evaluation of the Safety of Intramuscular BOTOX Purified Neurotoxin Complex Manufactured from Neurotoxin Complex batch BCB 2024 in the Management of Cervical Dystonia, Cynthia L. Comella, M.D. (Site: Principal Investigator).

AN073-351 (Comella)

9/22/1997-9/14/2001

Athena Neurosciences

An Open-Label, Safety Study of Neurobloc™ (Botulinum Toxin Type B) in Patients with Cervical Dystonia

The aim of this research is to evaluate the safety of Botulinum Toxin Type B in patients with cervical dystonia using repeat doses.

Role: Site principal Investigator

CCOM 998 US01

3/15/2000-12/31/2001

Novartis Pharmaceuticals

A Multicenter, Double-blind, Placebo-controlled Study of the Tolerability and Effect of Entacapone in Parkinson's Subjects with End-of-Dose Wearing Off Symptoms Occurring No Earlier than 4 Hours after their Most Recent Levodopa/Carbidopa Dose.

Role: Site Principal Investigator

Parkinson Study Group/ Dystonia Study Group

Parkinson Study Group. Determination of the dose response and plasma concentrations response of lazabemide (Ro 19-6327) in delaying the time until treatment with levodopa/carbidopa is required in Parkinson's Disease patients. Cynthia L. Comella, Principal Investigator).

Parkinson Study Group. A Multicenter, Double-Blind Placebo Controlled Parallel Group Dose Ranging Study of the Safety and Tolerability and Efficacy of Daily Oral Doses of Remacemide Hydrochloride in Parkinson Disease Subjects with Motor Fluctuations, Cynthia L. Comella, M.D. (Site: Principal Investigator)

Parkinson Study Group. A Double-Blind Placebo Controlled Parallel Group Dose Ranging Study for the Safety, Tolerability and Efficacy of SIB-1508Y in Parkinson's Disease Patients who are Requiring but Not Receiving Dopaminergic Therapy, Cynthia L. Comella, M.D. (Site Principal Investigator).

The Parkinson Study Group. Pramipexole Pharmacokinetics in Minority Populations. Caroline M. Tanner, M.D. (Principal Investigator); Cynthia L. Comella, M.D. (Co-Investigator and Steering Committee Member). Funding Source: UpJohn Company, 1996.

Dystonia Study Group

9/1/2000- 5/1/2002

The Development of a Unified Dystonia Rating Scale.

Dystonia Medical Research Foundation.

Cynthia L. Comella, M.D. (Chair: steering committee/Principal Investigator).

Dystonia Study Group

DSG2000.R01 (Comella)

3/1/2001-3/31/2005

A Randomized, Multi-Center, Double-Blind, Parallel Group Study Comparing BOTOX (Botulinum Toxin Type A) and Myobloc (Botulinum Toxin Serotype B) in Cervical Dystonia (CD) Subjects Responsive to Botulinum Toxin Type A.

Role: Chair, steering committee/Principal Investigator of study/Site Principal Investigator

Advisory Panels

Pain and Botulinum Toxin Advisory Board, Orlando, FL

Botulinum Toxin for Myofascial Pain: Advisory Board

Allergan Pharmaceuticals: Botulinum toxins

Advisory Board: Intrathecal Baclofen for Dystonia

Medtronic, Minneapolis, MN

RLS National Advisory Board: Glaxo

RLS Advisory Board: Pharmacia

PUBLICATIONS

1. Penn RD, Goetz CG, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt TR. The adrenal medullary transplant operation for parkinson's disease: Clinical observations in five patients. *Neurosurgery*. 1988 Jun; 22(6 Pt 1): 999-1004.
2. Comella CL, Bleck T. Selecting the right neurologic test for critically ill patients. *The Journal of Critical Care Medicine* 30, 1988; 47-58.
3. Comella CL, Bleck T. The technique of the lumbar puncture. *The Journal of Critical Care Medicine* 30, 1988; 61-66.
4. Goetz CG, Olanow CW, Koller WC, Penn RD, Cahill D, Morantz R, Stebbins G, Tanner CM, Klawans HL, Shannon KM. Multicenter study of autologous adrenal medullary transplantation to the corpus striatum in patients with advanced parkinson's disease. *N Engl J Med*. 1989 Feb 9; 320(6): 337-341.
5. Goetz CG, Tanner CM, Penn RD, Stebbins GT,3rd, Gilley DW, Shannon KM, Klawans HL, Comella CL, Wilson RS, Witt T. Adrenal medullary transplant to the striatum of patients with advanced parkinson's disease: 1-year motor and psychomotor data. *Neurology*. 1990 Feb; 40(2): 273-276.
6. Olanow CW, Koller W, Goetz CG, Stebbins GT, Cahill DW, Gauger LL, Morantz R, Penn RD, Tanner CM, Klawans HL, Shannon KM, Comella CL, Witt T. Autologous transplantation of adrenal medulla in parkinson's disease. 18-month results. *Arch Neurol*. 1990 Dec; 47(12): 1286-1289.
7. Diederich N, Goetz CG, Comella CL. New approaches in the treatment of the dystonias. *Klin Wochenschr*. 1990 Oct 3; 68(19): 935-941.
8. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin injection for spasmodic torticollis: Increased magnitude of benefit with electromyographic assistance. *Neurology*. 1992 Apr; 42(4): 878-882.

9. Comella CL, Tanner CM, DeFoor-Hill L, Smith C. Dysphagia after botulinum toxin injections for spasmodic torticollis: Clinical and radiologic findings. *Neurology*. 1992 Jul; 42(7): 1307-1310.
10. A controlled trial of lazabemide (RO19-6327) in untreated parkinson's disease. parkinson study group. *Ann Neurol*. 1993 Apr; 33(4): 350-356.
11. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in parkinson's disease patients with treatment-induced hallucinations. *Ann Neurol*. 1993 Nov; 34(5): 710-714.
12. Buchman AS, Comella CL, Stebbins GT, Tanner CM, Goetz CG. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. *Clin Neuropharmacol*. 1993 Jun; 16(3): 205-210.
13. Comella CL, Goetz CG. Akathisia in parkinson's disease. *Mov Disord*. 1994 Sep; 9(5): 545-549.
14. A controlled trial of lazabemide (ro 19-6327) in levodopa-treated parkinson's disease. parkinson study group. *Arch Neurol*. 1994 Apr; 51(4): 342-347.
15. Buchman AS, Comella CL, Stebbins GT, Weinstein SL. Determining a dose-effect curve for botulinum toxin in the sternocleidomastoid muscle in cervical dystonia. *Clin Neuropharmacol*. 1994; 17(2): 188-195.
16. Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and parkinson's disease: A controlled clinical trial. *Neurology*. 1994 Mar; 44(3 Pt 1): 376-378.
17. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders. report of the therapeutics and technology assessment subcommittee of the american academy of neurology. *Neurology*. 1994 Dec; 44(12): 2401-2403.
18. Cerebrospinal fluid homovanillic acid in the DATATOP study on parkinson's disease. parkinson study group. *Arch Neurol*. 1995 Mar; 52(3): 237-245.
19. Effect of lazabemide on the progression of disability in early parkinson's disease. the parkinson study group. *Ann Neurol*. 1996 Jul; 40(1): 99-107.
20. Diederich NJ, Comella CL, Goetz CG. Botulin toxin: Principles of action and neurological indications. *Presse Med*. 1997 Feb 1; 26(2): 96-100.
21. Entacapone improves motor fluctuations in levodopa-treated parkinson's disease patients. parkinson study group. *Ann Neurol*. 1997 Nov; 42(5): 747-755.
22. Safety and efficacy of pramipexole in early parkinson disease. A randomized dose-ranging study. parkinson study group. *JAMA*. 1997 Jul 9; 278(2): 125-130.

23. Diederich NJ, Comella CL, Matge G, Becker G, Schiltz F, Metz H. Sustained effect of high-dose intrathecal baclofen in primary generalized dystonia: A 2-year follow-up study. *Mov Disord.* 1997 Nov; 12(6): 1100-1102.
24. Comella CL, Stebbins GT, Goetz CG, Chmura TA, Bressman SB, Lang AE. Teaching tape for the motor section of the toronto western spasmodic torticollis scale. *Mov Disord.* 1997 Jul; 12(4): 570-575.
25. Buchman AS, Comella CL, Leurgans S, Stebbins GT, Goetz CG. The effect of changes in head posture on the patterns of muscle activity in cervical dystonia (CD). *Mov Disord.* 1998 May; 13(3): 490-496.
26. Comella CL, Shannon KM, Jaglin J. Extensor truncal dystonia: Successful treatment with botulinum toxin injections. *Mov Disord.* 1998 May; 13(3): 552-555.
27. Comella CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in parkinson's disease. *Neurology.* 1998 Aug; 51(2): 526-529.
28. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with parkinson's disease. *Ann Neurol.* 1999 Sep; 46(3): 419-424.
29. Comella CL, Shannon KM. Hemiballismus. *Curr Treat Options Neurol.* 1999 Mar; 1(1): 1-5.
30. Low-dose clozapine for the treatment of drug-induced psychosis in parkinson's disease. the parkinson study group. *N Engl J Med.* 1999 Mar 11; 340(10): 757-763.
31. Brin MF, Lew MF, Adler CH, Comella CL, Factor SA, Jankovic J, O'Brien C, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. *Neurology.* 1999 Oct 22; 53(7): 1431-1438.
32. Brashear A, Lew MF, Dykstra DD, Comella CL, Factor SA, Rodnitzky RL, Trosch R, Singer C, Brin MF, Murray JJ, Wallace JD, Willmer-Hulme A, Koller M. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. *Neurology.* 1999 Oct 22; 53(7): 1439-1446.
33. Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with parkinson's disease. *Neurology.* 2000 Nov 28; 55(10): 1572-1575.
34. A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. parkinson study group. *Neurology.* 2000 Nov 28; 55(10): 1540-1547.
35. Comella CL, Jankovic J, Brin MF. Use of botulinum toxin type A in the treatment of cervical dystonia. *Neurology.* 2000; 55(12 Suppl 5): S15-21.

36. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K, Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial. *Mov Disord*. 2001 Jan; 16(1): 135-139.
37. Pfann KD, Buchman AS, Comella CL, Corcos DM. Control of movement distance in parkinson's disease. *Mov Disord*. 2001 Nov; 16(6): 1048-1065.
38. Kompoliti K, Goetz CG, Leurgans S, Raman R, Comella CL. Estrogen, progesterone, and tic severity in women with gilles de la tourette syndrome. *Neurology*. 2001 Oct 23; 57(8): 1519.
39. Weiner WJ, Factor SA, Jankovic J, Hauser RA, Tetrud JW, Waters CH, Shulman LM, Glassman PM, Beck B, Paume D, Doyle C. The long-term safety and efficacy of pramipexole in advanced parkinson's disease. *Parkinsonism Relat Disord*. 2001 Apr; 7(2): 115-120.
40. Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B, Parkinson Study Group. A randomized, controlled trial of remacemide for motor fluctuations in parkinson's disease. *Neurology*. 2001 Feb 27; 56(4): 455-462.
41. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Comella CL, Dubinsky RM, Friedman JH, Manyam BV, Matsumoto JY, Pullman SL, Rajput AH, Sethi KD, Tanner C, Koller WC. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. *Neurology*. 2001 Jun 12; 56(11): 1523-1528.
42. Louis ED, Barnes L, Wendt KJ, Ford B, Sangiorgio M, Tabbal S, Lewis L, Kaufmann P, Moskowitz C, Comella CL, Goetz CC, Lang AE. A teaching videotape for the assessment of essential tremor. *Mov Disord*. 2001 Jan; 16(1): 89-93.
43. Comella CL. Daytime sleepiness, agonist therapy, and driving in parkinson disease. *JAMA*. 2002 Jan 23-30; 287(4): 509-511.
44. Robichaud JA, Pfann KD, Comella CL, Corcos DM. Effect of medication on EMG patterns in individuals with parkinson's disease. *Mov Disord*. 2002 Sep; 17(5): 950-960.

45. Comella CL. Restless legs syndrome: Treatment with dopaminergic agents. *Neurology*. 2002 Feb 26; 58(4 Suppl 1): S87-92.
46. Lyons KE, Pahwa R, Comella CL, Eisa MS, Elble RJ, Fahn S, Jankovic J, Juncos JL, Koller WC, Ondo WG, Sethi KD, Stern MB, Tanner CM, Tintner R, Watts RL. Benefits and risks of pharmacological treatments for essential tremor. *Drug Saf*. 2003; 26(7): 461-481.
47. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, Parkinson Study Group. Longitudinal outcome of parkinson's disease patients with psychosis. *Neurology*. 2003 Jun 10; 60(11): 1756-1761.
48. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Jr, Lozano AM, Penn RD, Simpson RK, Jr, Stacy M, Wooten GF, ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. *Neurology*. 2003 Jan 14; 60(1): 69-73.
49. Comella CL, Leurgans S, Wu J, Stebbins GT, Chmura T, Dystonia Study Group. Rating scales for dystonia: A multicenter assessment. *Mov Disord*. 2003 Mar; 18(3): 303-312.
50. Comella CL. Sleep disturbances in parkinson's disease. *Curr Neurol Neurosci Rep*. 2003 Mar; 3(2): 173-180.
51. Comella C. Sleep episodes in parkinson's disease: More questions remain. *Sleep Med*. 2003 Jul; 4(4): 267-268.
52. Goldman JG, Comella CL. Treatment of dystonia. *Clin Neuropharmacol*. 2003 Mar-Apr; 26(2): 102-108.
53. Comella CL, Pullman SL. Botulinum toxins in neurological disease. *Muscle Nerve*. 2004 May; 29(5): 628-644.
54. Robichaud JA, Pfann KD, Comella CL, Brandabur M, Corcos DM. Greater impairment of extension movements as compared to flexion movements in parkinson's disease. *Exp Brain Res*. 2004 May; 156(2): 240-254.
55. Pfann KD, Robichaud JA, Gottlieb GL, Comella CL, Brandabur M, Corcos DM. Muscle activation patterns in point-to-point and reversal movements in healthy, older subjects and in subjects with parkinson's disease. *Exp Brain Res*. 2004 Jul; 157(1): 67-78.
56. Dystonia Study Group. Rating scales for dystonia: Assessment of reliability of three scales. *Adv Neurol*. 2004; 94: 329-336.
57. Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W, Dystonia Study Group. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. *Neurology*. 2005 Nov 8; 65(9): 1423-1429.

58. Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL. Efficacy and safety of botulinum type A toxin (dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. *Mov Disord.* 2005 Jul; 20(7): 783-791.
59. Robichaud JA, Pfann KD, Vaillancourt DE, Comella CL, Corcos DM. Force control and disease severity in parkinson's disease. *Mov Disord.* 2005 Apr; 20(4): 441-450.
60. Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in parkinson disease: A controlled study using actigraphy. *Neurology.* 2005 Apr 26; 64(8): 1450-1451.
61. Hinson VK, Cubo E, Comella CL, Goetz CG, Leurgans S. Rating scale for psychogenic movement disorders: Scale development and clinimetric testing. *Mov Disord.* 2005 Dec; 20(12): 1592-1597.
62. Itin I, Comella CL. Restless legs syndrome. *Prim Care.* 2005 Jun; 32(2): 435-448.
63. Widnell KL, Comella C. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. *Mov Disord.* 2005; 20 Suppl 11: S30-7.
64. Park M, Comella CL, Leurgans SE, Fan W, Wilson RS, Bennett DA. Association of daytime napping and parkinsonian signs in alzheimer's disease. *Sleep Med.* 2006 Dec; 7(8): 614-618.
65. Comella CL. Can families be screened for cervical dystonia using a telephone interview? *Nat Clin Pract Neurol.* 2006 Jan; 2(1): 20-21.
66. Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ. Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia. *Neurology.* 2006 Dec 26; 67(12): 2233-2235.
67. Prodoehl J, MacKinnon CD, Comella CL, Corcos DM. Rate of force production and relaxation is impaired in patients with focal hand dystonia. *Parkinsonism Relat Disord.* 2006 Sep; 12(6): 363-371. PMID: PMC2094389.
68. Comella CL. Sleep disturbances and excessive daytime sleepiness in parkinson disease: An overview. *J Neural Transm Suppl.* 2006; (70)(70): 349-355.
69. Prodoehl J, MacKinnon CD, Comella CL, Corcos DM. Strength deficits in primary focal hand dystonia. *Mov Disord.* 2006 Jan; 21(1): 18-27.
70. Comella CL, Thompson PD. Treatment of cervical dystonia with botulinum toxins. *Eur J Neurol.* 2006 Feb; 13 Suppl 1: 16-20.

71. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, Marsh L, Nail L, Shulman L, Taylor CB, Working Group on Fatigue in Parkinson's Disease. Fatigue in parkinson's disease: A review. *Mov Disord.* 2007 Feb 15; 22(3): 297-308.
72. Iranzo A, Comella CL, Santamaria J, Oertel W. Restless legs syndrome in parkinson's disease and other neurodegenerative diseases of the central nervous system. *Mov Disord.* 2007; 22 Suppl 18: S424-30.
73. Comella CL. Sleep disorders in parkinson's disease: An overview. *Mov Disord.* 2007 Sep; 22 Suppl 17: S367-73.
74. Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the therapeutics and technology assessment subcommittee of the american academy of neurology. *Neurology.* 2008 May 6; 70(19): 1699-1706.
75. Prodoehl J, Corcos DM, Leurgans S, Comella CL, Weis-McNulty A, MacKinnon CD. Changes in the relationship between movement velocity and movement distance in primary focal hand dystonia. *J Mot Behav.* 2008 Jul; 40(4): 301-313. PMID: PMC2657478.
76. Truong D, Comella C, Fernandez HH, Ondo WG, Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (dysport) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. *Parkinsonism Relat Disord.* 2008; 14(5): 407-414.
77. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S, Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with parkinson disease. *Neurology.* 2008 Aug 12; 71(7): 481-485.
78. Brin MF, Comella CL, Jankovic J, Lai F, Naumann M, CD-017 BoNTA Study Group. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. *Mov Disord.* 2008 Jul 30; 23(10): 1353-1360.
79. Weintraub D, Comella CL, Horn S. Parkinson's disease--part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. *Am J Manag Care.* 2008 Mar; 14(2 Suppl): S40-8.
80. Weintraub D, Comella CL, Horn S. Parkinson's disease--part 2: Treatment of motor symptoms. *Am J Manag Care.* 2008 Mar; 14(2 Suppl): S49-58.
81. Weintraub D, Comella CL, Horn S. Parkinson's disease--part 3: Neuropsychiatric symptoms. *Am J Manag Care.* 2008 Mar; 14(2 Suppl): S59-69.
82. Comella CL. Sleep disorders in parkinson's disease. *Curr Treat Options Neurol.* 2008 May; 10(3): 215-221.

83. Comella CL. The treatment of cervical dystonia with botulinum toxins. *J Neural Transm.* 2008; 115(4): 579-583.
84. Marder K, Zhao H, Eberly S, Tanner CM, Oakes D, Shoulson I, Huntington Study Group. Dietary intake in adults at risk for huntington disease: Analysis of PHAROS research participants. *Neurology.* 2009 Aug 4; 73(5): 385-392. PMID: PMC2725927.
85. Vaillancourt DE, Spraker MB, Prodoehl J, Abraham I, Corcos DM, Zhou XJ, Comella CL, Little DM. High-resolution diffusion tensor imaging in the substantia nigra of de novo parkinson disease. *Neurology.* 2009 Apr 21; 72(16): 1378-1384. PMID: PMC2677508.
86. Alcalay RN, Mejia-Santana H, Tang MX, Rosado L, Verbitsky M, Kisselev S, Ross BM, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Caccappolo E, Ottman R, Clark LN, Marder KS. Motor phenotype of LRRK2 G2019S carriers in early-onset parkinson disease. *Arch Neurol.* 2009 Dec; 66(12): 1517-1522. PMID: PMC2837584.
87. Zuber SE, Watson N, Comella CL, Bakay RA, Metman LV. Stimulation-induced parkinsonism after posteroventral deep brain stimulation of the globus pallidus internus for craniocervical dystonia. *J Neurosurg.* 2009 Feb; 110(2): 229-233.
88. Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early parkinson's disease. part 1. *Eur Neurol.* 2009; 61(4): 193-205.
89. Simuni T, Lyons KE, Pahwa R, Hauser RA, Comella C, Elmer L, Weintraub D. Treatment of early parkinson's disease. part 2. *Eur Neurol.* 2009; 61(4): 206-215.
90. Hallett M, Benecke R, Blitzer A, Comella CL. Treatment of focal dystonias with botulinum neurotoxin. *Toxicon.* 2009 Oct; 54(5): 628-633.
91. Robichaud JA, Pfann KD, Leurgans S, Vaillancourt DE, Comella CL, Corcos DM. Variability of EMG patterns: A potential neurophysiological marker of parkinson's disease? *Clin Neurophysiol.* 2009 Feb; 120(2): 390-397. PMID: PMC2679966.
92. Alcalay RN, Mejia-Santana H, Tang MX, Rakitin B, Rosado L, Ross B, Verbitsky M, Kisselev S, Louis ED, Comella CL, Colcher A, Jennings D, Nance MA, Bressman S, Scott WK, Tanner C, Mickel SF, Andrews HF, Waters CH, Fahn S, Cote LJ, Frucht SJ, Ford B, Rezak M, Novak K, Friedman JH, Pfeiffer R, Marsh L, Hiner B, Siderowf A, Ottman R, Clark LN, Marder KS, Caccappolo E. Self-report of cognitive impairment and mini-mental state examination performance in PRKN, LRRK2, and GBA carriers with early onset parkinson's disease. *J Clin Exp Neuropsychol* 2010; 24:1-5.
93. Marder KS, Tang MX, Mejia-Santana H, Rosado L, Louis ED, Comella CL, Colcher A, Siderowf AD, Jennings D, Nance MA, Bressman S, Scott WK, Tanner CM, Mickel SF, Andrews HF, Waters C, Fahn S, Ross BM, Cote LJ, Frucht S, Ford B, Alcalay RN, Rezak M, Novak K, Friedman JH, Pfeiffer RF, Marsh L, Hiner B, Neils GD, Verbitsky M, Kisselev S, Caccappolo E, Ottman R, Clark LN. Predictors of parkin mutations in early-

onset parkinson disease: The consortium on risk for early-onset parkinson disease study. *Arch Neurol* 2010; 67(6):731-738.

94. Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in parkinson's disease: The PROUD study. *Mov Disord* 2010; 25(11):1627-1632.
95. Menza M, Dobkin RD, Marin H, Gara M, Bienfait K, Dicke A, Comella CL, Cantor C, Hyer L. Treatment of insomnia in parkinson's disease: A controlled trial of eszopiclone and placebo. *Mov Disord* 2010; 25(11):1708-1714.
96. Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE. Basal ganglia hypoactivity during grip force in drug naive parkinson's disease. *Hum Brain Mapp.* 2010 Mar 11 [Epub ahead of print].

BOOKS, CHAPTERS, AND REVIEWS:

1. **Comella CL**, Tanner CM. Anticholinergic drugs in Parkinson's disease. In: Koller WC, Paulson G (eds). *Therapy for Parkinson's disease*. New York: Marcel Dekker; 1990:123-141. (Revised edition, 1994)
2. Goetz CG, Tanner CM, Penn RD, Stebbins GT, Shannon KM, Klawans HL, **Comella CL**, Brown-Toms N, Carroll VS, Witt T. Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: The Chicago experience at 12-months. Liebermann AN (ed.) *Neural Transplantation*, 1990.
3. Diederich N, Goetz CG, **Comella CL**. New Approaches to the Treatment of Dystonia. *Klin Wochenschr* 1990; 68:935-941.
4. **Comella CL**, Tanner CM. The side effects of chronic treatment in Parkinson's disease. In: *Disorders of Movement in Psychiatry and Neurology*. A.B. Joseph, R.R. Young (eds.) Blackwell, 1992.
5. **Comella CL**, Tanner CM. Four unusual movement disorders: painful legs and moving toes, periodic movements in sleep, restless legs syndrome, and akathisia. In: Klawans HL, Goetz CG, Tanner CM (eds.). *Textbook of Clinical Neuropharmacology and Therapeutics*, 2nd edition. New York: Raven Press, pp. 215-228, 1992.
6. **Comella CL**, Klawans HL. Non-parkinsonian movement disorders in the elderly. In: Albert ML, Knoefel. *J Clinical Neurology of Aging*. Oxford Press, 1992.
7. **Comella CL**. Blinded striatopallidal califications. In: Stern MB, Koller WC (eds.). *Parkinsonian Syndromes*. New York: Marcel Dekker 1993: 483-501.

8. **Comella CL**, Buchman AS, Stebbins GT. The usefulness of electromyography in botulinum treatment of cervical dystonia. In: DasGupta BR. *Botulinum and Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects*. New York: Plenum Press, 1993.
9. **Comella CL**. Electromyography-assisted botulinum toxin injections for the treatment of cervical dystonia. In: Jankovic J, Hallett M (eds.). *Botulinum Toxin Treatment*. Marcel Dekker, 1994.
10. **Comella CL**. Dystonia. In: Feldman E (ed.). *Current Diagnosis in Neurology*. Philadelphia, PA: Mosby-Year Book, Inc., 1994.
11. Brandabur MM, **Comella CL**. Movement disorders. In: Bone RC, Rosen RL. *Quick Reference to Internal Medicine*. New York: Igaku-Shoin Medical Publishers, 1994.
12. Jankovic J, Brin MF, **Comella CL**. Botulinum toxin treatment of cervical dystonia. New York: Churchill Livingstone, 1994.
13. **Comella CL**. Botulinum toxin treatment of focal dystonia. *Neurology Forum* 1994; 5:2-14.
14. Brin MF, Jankovic J, **Comella CL**, Blitzer A, Tsui J, Pullman SL. Treatment of dystonia using botulinum toxin. In : Kurlan R (ed.). *Treatment of Movement Disorders*. Philadelphia: JB Lippincott Co, pp.183-246, 1995.
15. **Comella CL**, Tanner CM. Anticholinergic drugs in the treatment of Parkinson's disease. In: *Therapy of Parkinson's Disease*, 2nd edition. Koller WC, Paulson G, ed. Marcel Dekker, Inc., New York, 1995.
16. **Comella CL**. Sleep in the elderly. In: Sage J, Mark M (eds.). *Practical Neurology of the Elderly*, pp. 399-450. Marcel Dekker, Inc., 1996.
17. **Comella CL**. Idiopathic dystonia. In: *Prognosis in Neurology*, James M. Gilchrist, ed., pp. 161-166. Butterworth-Heinemann: Boston, 1998.
18. Kompoliti A, **Comella CL**. Non-parkinsonian movement disorders in the elderly. In: Pathy MSJ, ed., *Principles and Practice of Geriatric Medicine*, 3rd ed. John Wiley and Sons, 1998.
19. **Comella CL**, Henning W, Walters A. Sleep and wakefulness. In: Goetz CG, Pappert EJ, eds. *Textbook of Clinical Neurology*, 1st edition, pp., 17-29. W.B. Saunders Company, Philadelphia, 1999.
20. **Comella CL**, Tanner CL. The side effects of chronic treatment in Parkinson's disease. In: *Movement Disorders in Neurology and Psychiatry*, 2nd edition. Anthony B. Joseph and Robert R. Young, eds., pp. 209-216. Blackwell Science, Inc., Malden, MA, 1999.

21. **Comella CL.** Drug-induced movement disorders. In: *Movement Disorders in Clinical Practice*. Guy Sawle, ed., pp. 165-182. Isis Medical Media, Ltd. Nottingham, UK, 1999.
22. Goetz CG, **Comella CL.** Neurotoxic effects of drugs prescribed by non-neurologists. In: *Neurology for the Non-Neurologist*, 4th ed., pp. 245-261. Lippincott-Williams & Wilkins: Philadelphia, 1999.
23. **Comella CL.** Sleep and Parkinson's disease. In: *Parkinson's disease and Movement Disorders: Diagnosis and Treatment Guidelines for Practicing Physicians*. Charles H. Adler, J. Eric Ahlskog, eds, pp. 151-160. Humana Press: Totowa, NJ, 2000.
24. **Comella CL.** Sleep Disorders. In: *Parkinson's Disease: Diagnosis and Clinical Management*, eds., Stewart A. Factor & William J. Weiner, pp. 101-108. Demos Medical Publishing, Inc., 2002.
25. Stevens S, **Comella CL**, Walters A, Henning WA. Sleep and wakefulness. In: Goetz CG, editor. *Textbook of Clinical Neurology*. Philadelphia PA, Elsevier Science 2003:pp 19-31.
26. **Comella CL**, Ludlow C, Hallet M. Focal Dystonias. In: Noseworthy J (editor). *Neurological Therapeutics: Principles and Practice*. New York: Martin Dunitz, Ltd 2003: Chapter 239.
27. **Comella CL.** Presentation of excessive sleepiness in Parkinson's Disease. *Treatment Reporter*. 2003.
28. **Comella CL**, Simpson LL, Jankovic J. Botulinum toxins: Transformation of a toxin into a treatment. In: Waxman S. *Neuroscience, Molecular Medicine, and the Therapeutic Transformation of Neurology*. Philadelphia, PA, Elsevier Science. 2004.
29. Brin M, Jankovic J, **Comella CL.** (editors): *Dystonia Monograph: Progress in Dystonia*. Lippincott publishers, 2004
30. **Comella CL.** Sleep Disorders in Parkinson's Disease: In: Galvez N (editor). *Scientific Basis for the treatment of Parkinson's Disease*. In press 2004.
31. Brin M, **Comella CL**, Jankovic J. *Dystonia: Etiology, Clinical Features, and Treatment*. Lippincott Williams & Wilkins, 2004.
32. **Comella CL**, Shannon KM (editors). *Continuum: Movement Disorders*. American Academy of Neurology. Philadelphia: Lippincott Williams & Williams, June 2004.

33. **Comella, CL.** Dystonia and Related Diseases. In: Comella CL, Shannon KM (editors). *Continuum: Movement Disorders*. Lippincott Williams & Williams, 2004; Vol 10:89-112.
34. **Comella CL.** Gilles de la Tourette Syndrome and other tic disorders. In: Comella CL, Shannon KM (editors). *Continuum: Movement Disorders*. Lippincott Williams & Williams, 2004; Vol 10:128-141.
35. Videnovic A, **Comella CL.** Sleep in Parkinson disease. *Handbook of Clinical Neurology*, 2006 (in press)

ABSTRACTS

1. **Comella CL,** Tanner CM, Goetz CG, Ropp D, Ganz S, Fisher J. Debrisoquine metabolism in Parkinson's disease. *Neurology* 1987; 37(Suppl 1):334.
2. **Comella CL,** Klawans HL. Meige's syndrome in twins. *Neurology* 1988; 38(Suppl 1): 315.
3. **Comella CL,** Ristanovic RK, Tanner CM, Lloyd S. Quantitative sleep studies in Parkinson's disease. *Neurology* 1989; 39(Suppl 1): 421.
4. Shannon KS, **Comella CL,** Tanner CM. EMG-guided botulinum toxin injections in torticollis: objective clinical improvements. *Neurology* 1989; 39(Suppl 1):352.
5. **Comella CL,** Goetz CG. Akathisia in Parkinson's disease. *Annals of Neurology* 1989; 26:164.
6. **Comella CL,** Tanner CM, DeFoor L, Smith C. Dysphagia after botulinum toxin injection for spasmodic torticollis. *Neurology* 1990; 40(Suppl 1).
7. **Comella CL,** Buchman A, Tanner CM. The frequency of dysphagia after botulinum toxin. *Movement Disorders* 1990;1 5(Suppl 1):75.
8. Buchman AB, **Comella CL,** Garrat MJ, Tanner CM. Quantitative EMG analysis of response to botulinum toxin therapy for spasmodic torticollis. *Annals of Neurology* 1990; 28:268.
9. **Comella CL,** Buchman AB, Tanner CM, Goetz CG, Brown-Toms N. Clinical versus EMG-guided BOTOX injections for the treatment of spasmodic torticollis. *Neurology* 1991; 41(Suppl 1): 273-274.

10. Stebbins GT, Gilley DW, Goetz CG, Tanner CM, Wilson RS, **Comella CL**, Klawans HL. Quality of life in Parkinson disease patients at two years following adrenal medulla/caudate implant. *Neurology* 1991; 30:295.
11. **Comella CL**, Tanner CM, Ristanovic R. Quantitative sleep studies in Parkinson's disease. *Annals of Neurology* 1991; 30:295.
12. Stebbins GT, **Comella CL**. Quality of life measures in cervical dystonia: before and following botulinum toxin injections. *Movement Disorders* 1992; 7(Suppl 1):135.
13. **Comella CL**, Stebbins GT. A crossover study of physical rehabilitation in Parkinson's disease. *Annals of Neurology* 1992; 32:261A.
14. Stebbins GT, Singh J, Gabrieli JDE, **Comella CL**, Goetz CG. Impaired working memory in unmedicated adults with Gilles de la Tourette syndrome. *Soc Neuroscience Abs* 1992; 13:1213.
15. **Comella CL**, Ristanovic R, Goetz CG. Parkinson disease patients with and without REM behavior disorder (RBD): A polysomnographic and clinical comparison. *Neurology* 1993; 43:A301.
16. **Comella CL**, Carson V. The effect of Parkinson disease severity and antiparkinson medication on sleep duration and sleep fragmentation. *Annals of Neurology* 1993; 34:A302.
17. Buchman AS, **Comella CL**, Stebbins GT, Weinstein S, Goetz CG. Determining a dose-effect curve for botulinum toxin injections into the cleidomastoid muscle in cervical dystonia. *Annals of Neurology* 1993; 34:A265.
18. Stebbins GT, **Comella CL**, Gabrieli JDE, Burton K, Singh S. Working memory, perceptual speed, and motor dysfunction in Parkinson's disease. *Neurology* 1994; 44(Suppl 2):A195.
19. Shannon KM, Goldner FS, **Comella CL**, Goetz CG, Stebbins GT. Dopaminergic pharmacology of bradykinesia in Huntington's disease. *Neurology* 1994; 44(Suppl 2):A398.
20. **Comella CL**, Shannon KM, Jaglin J. The usefulness of botulinum toxin for the treatment of truncal dystonia. *Movement Disorders* 1994; 4:488.
21. **Comella CL**, Boehm J, Stebbins GT. Sleep benefit in Parkinson's disease. *Neurology* 1995; 45:286.
22. Jong L, **Comella CL**, Jaglin J. Menstrual-related cyclic changes in Parkinson's disease. *Neurology* 1995; 45:337.

23. **Comella CL**, Miller S, Buchman AS. The geste antagoniste in cervical dystonia: frequency and associated factors. *Annals of Neurology* 1995;38:328-329.
24. **Comella CL**, Stebbins GT, Chmura TA, Bressman SB, Goetz CG, Lang AE. Toronto Western Spasmodic Torticollis Scale: a teaching videotape and interrater reliability. *Movement Disorders* 1995; 10(5): A698.
25. **Comella CL**, Buchman AS. Factors associated with disability in cervical dystonia. *Neurology* 1996; 46:A259.
26. **Comella CL**, Stebbins GT, Jaglin J. Comparison of clinical features of Parkinson's disease between African-Americans and Caucasians in a referral setting. *Movement Disorders* 1996;11:159.
27. Diederich N, Matge G, Becker G, **Comella CL**, Schilz F, Metz H. Long-term use of intrathecal Baclofen for generalized dystonia: a case study. *Movement Disorders* 1996; 11(S1):215.
28. Goetz CG, **Comella CL**. Rating scales in movement disorders. *Movement Disorders* 1996; 11(1):A30.
29. **Comella CL**, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury and REM sleep behavior disorder in Parkinson's disease. *Neurology* 1997; 48:A359.
30. **Comella CL**, Nardine T, Toehmer J, Stebbins GT. Sleep benefit in Parkinson's disease. *Annals of Neurology*, 1997.
31. **Comella CL**. Peripheral denervation surgery for the treatment of cervical dystonia. International Congress of Movement Disorders. *Movement Disorders*.
32. **Comella CL**, Goetz CG, Leurgans S, Chmura T. Selective peripheral denervation surgery in cervical dystonia patients resistant to botulinum toxin injections. *Movement Disorders* 1998; 13(2):A97.
33. **Comella CL**, Siemers ER, Goetz CG, Leurgans S, Stebbins GT and the Dystonia Study Group. Development of the Unified Dystonia Rating Scale: assessment of reliability. *Neurology* 1998; 50:A365.
34. **Comella CL**, Tanner CM. Sleep disturbance and hallucinations in Parkinson's disease: results of quantitative sleep studies. *Annals of Neurology* 1998; A295.
35. Brashear A, Lew MF, Dykstra DD, **Comella CL**, Factor SA, Rodnitzky RL, Trosch R, Singer CV, Brin MF, Murray JJ, Wilmer-Hulme A, Wallace JD, Koller M. Safety and efficacy of Neurobloc™ (Botulinum toxin type-B) in type A-responsive cervical dystonia patients. *Neurology* 1999; 52(Suppl 2): A292.

36. Brin MF, Lew MF, Adler CH, **Comella CL**, Factor SA, Jankovic J, O'Brien CF, Murray JJ, Wallace JD, Wilmer-Hulme A, Koller M. Safety and efficacy of neurobloc™ (Botulinum toxin type-B) in type A-resistant cervical dystonia (CD) patients. *Neurology* 1999; 52(Suppl 2):A293.
37. **Comella CL**, Leurgans S, Chmura TA and the Dystonia Study Group. The Unified Dystonia Rating Scale: initial concurrent validity testing with other dystonia scales. *Neurology* 1999; 52(Suppl 2): A292.
38. Kordower JH, Palfi S, Mufson EJ, Levey AI, Chen E-Y, Ma S, Cochran EJ, Penn RD, Gash DM, **Comella CL**. Clinico-pathological findings following intraventricular GDNF treatment in a patient with Parkinson's disease. *Neurology* 1999; 52(Suppl 2):A4.
39. Diederich NJ, Pieri V, **Comella CL**. REM sleep behavior disorder in parkinsonism: diagnosis by interviewing the caregiver. *Movement Disorders* 1999; 15(Suppl 1):185.
40. Hauser RA, **Comella CL**, Brashear A, Troung D, Chalres PD, Tsui J, Botox® 140-8051 Study Group: Mordaunt J, Nordquist M, Bugarin D. Randomized multicener, double-blind, placebo-controlled study of original Botox® (Botulinum toxin Type-A) purified neurotoxin complex for the treatment of cervical dystonia. *Movement Disorders* 2000; 15(2):A30.
41. Goetz CG, Leurgans S, Raman R, and the **Parkinson Study Group**. Placebo-related improvements in motor function in early Parkinson's disease. *Annals of Neurology* 2000; 48(3): A433.
42. Factor S, Adler CH, Brashear A, Brin MF, **Comella CL**, Dykstra DD, Jankovic J, Lew MF, O'Brien C, Rodnitzky RL. Safety and efficacy of neurobloc™ (Botulinum toxin Type B) in Type-A responsive and Type-A resistant patients with cervical dystonia. *Movement Disorders* 2000; 15(2):A7.
43. **Comella CL**. Botox® for cervical dystonia. *Movement Disorders* 2000; 15(2):A7.
44. Bourg G, Diederich NJ, **Comella CL**, Raman R, Leurgans S, Andreolli D, Azzolin J, Pauly F. Blinded video evaluation does not confirm functional gait improvement in lower limb spasticity after botulinum toxin injection. *Movement Disorders* 2000; 15(2):A47.
45. Brin MF, **Comella CL**, O'Brien C, Jankovic J, Benabou R, Jaglin J, Johnston T, Judd D, Hunter C. An interim analysis of the clinical status of patients receiving current Botox® (Lot 2024 or subsequent Lots) for the treatment of cervical dystonia (CD). *Movement Disorders* 2000.
46. Diederich NJ, Pieri V, **Comella CL**. REM sleep behavior disorder in parkinsonism: diagnosis by interviewing the caregiver. *Movement Disorders* 2000; 15(Suppl 3):A185.

47. **Comella CL**, Morrissey M, Leurgans S. Excessive daytime sleepiness in Parkinson's disease is associated with male gender and dopamine agonist therapy. *Annals of Neurology* 2000; 48(3):A432.
48. **Comella CL**, Jankovic J, Brin MF. Use of botulinum toxin type-A in the treatment of cervical dystonia. *Neurology* 2000; 55(Suppl 5):S15-21.
48. Kompoliti K, Goetz CG, Leurgans S, Raman R, **Comella CL**. Estrogen, progesterone, and tic severity in women with Gilles de la Tourette syndrome. *Neurology* 2001; 57(Oct. 2 of 2):1519.
49. Janko K, **Comella CL**, Morrissey M. A Comparison of subjective sleep quality measures and actigraphy in determining excessive daytime sleepiness. *Neurology April 2002; 58(Suppl 3):A435*.
50. **Comella CL**, Stevens S, Stepanski examination, Leurgans S. Sensitivity analysis of the clinical diagnostic criteria for REM Behavior Disorder (RBD) in Parkinson's disease. *Neurology April 2002;58(Suppl 3):A434*.
51. Castillo AE, Wlodarek CA, **Comella CL**, Morrissey M. Activities of daily living in Parkinson's disease: Comparison of patient and caregiver perceptions. *Neurology April 2002;58(Suppl 3):A468*.
52. Factor SA, Feustel PJ, Friedman JH, **Comella CL**, Goetz CG, Kurlan R, Parsa M, Pfeiffer rigidity, The Parkinson Study Group. Longitudinal outcome of Parkinson's disease patients with psychosis: Persistence of behavioral impairments, mortality, and nursing homes placement. *Movement Disorders 2002;17(5):1105*.
53. Truong D, **Comella C**, Hriedman JH, Carter J, Tanner C, Chawla S, Jenkins S, Huff FJ. Acute effects of Neotrofin in patients with Parkinson's disease. *Movement Disorders 2002;17(5):1106*
54. **Dystonia Study Group**, Wu J, Leurgans S, Stebbins GT. Inter-Rater agreement and factor analysis of the Global Dystonia Rating Scale. *Movement Disorders 2002;17(5):1109*.
55. **Comella CL**, Wu J, Leurgans S, The Dystonia Study Group. Inter-Rater agreement for the Ancillary Nonmotor Rating Scales included in the Unified Dystonia Rating Scale and the Burke-Fahn-Marsden Rating Scale for Dystonia. *Movement Disorders 2002;17(5):1142*.
56. Jaglin JA, **Comella CL**, Morrissey M. Fluctuations in self-assessed benefit following botulinum toxin type A treatment in cervical dystonia [P945]. *Movement Disorders 2002;17(5):S288*.

57. Truong DD, Duane DD, Jankovic J, Singer C, **Comella CL**, The U.S. Dysport Dystonia Study Group. The efficacy and safety of Dysport (botulinum type A toxin) in cervical dystonia: Results of the first U.S. study [P1007]. *Movement Disorders* 2002;17(5):S306.
58. **Comella CL**. REM sleep behavior disorder: A condition of sleep/state motor dysregulation linked to Lewy body diseases [PL38]. *Movement Disorders* 2002;17(5):S12.
59. Ahmed A, **Comella CL**, Rezai A. Chronic high frequency bilateral deep brain stimulation of the subthalamic-nucleus for juvenile-onset Parkinson's disease. *Neurology* 2003 Mar;60(5):A124
60. **Comella C**. Sleep episodes in Parkinson's disease: more questions remain. *Sleep Med.* 2003 Jul;4(4):267-8.
61. Hinson VK, Cubo E, **Comella CL**, Leurgans, Goetz CG. Rating scale for psychogenic movement disorders: a study of interrater agreement. *Neurology* 2003 Mar;60(5):A212.
62. Goldman JG, **Comella CL**. Treatment of dystonia. *Clin Neuropharmacol.* 2003 Mar-Apr;26(2):102-8.
63. **Comella CL**. Sleep disturbances in Parkinson's disease. *Curr Neurol Neurosci Rep.* 2003 Mar;3(2):173-80.
64. **Comella C**, Jankovic J, Daggett Sinemet, Mordaunt J, Brin M. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type a treatment for cervical dystonia. *Neurology* 2004 April;62(7 Suppl3);P06.141.
65. **Comella CL**, Pullman SL. Botulinum toxins in neurological disease. *Muscle Nerve.* 2004 May;29(5):628-44.
66. **Comella C**, Janko K, Morrissey M. Effects of nocturnal pergolide on sleep in Levodopa-treated Parkinson's disease patients: a randomized, placebo-controlled trial. *Neurology* April;62(7 Suppl 3);S38.2005.
67. **Comella, C**, Jankovic J, Leurgans S, Fan W, Chmura T and the Dystonia Study Group. Botulinum toxin serotype A compared to B in cervical dystonia: a randomized double-blind parallel study. *Ann Neurol* 2004; 56 (suppl 8): S25.
68. **Comella CL**, Jankovic J, Daggett Sinemet, Mordaunt J, Brin M. Interim results of an observational study of neutralizing antibody formation with the current preparation of botulinum toxin type a treatment for cervical dystonia. *Neurology* 2004 April;62(7 Suppl 3);P06.141.

69. **Comella CL**, Janko K, Morrissey M. Effects of nocturnal Pergolide on sleep in Levodopa-treated Parkinson's disease patients: a randomized, placebo-controlled trial. *Neurology* April;62(7 Suppl 3);S38.2005.
70. Jaglin J. A., **Comella CL**, Fan W., Leurgans SE. Increased self-reported stress decreases subjective improvement following botulinum toxin injections for cervical dystonia. *Movement Disorders* 20(Suppl 10):P98, 2005.
71. Barbano RL, **Comella CL**, Fan W, Leurgans SE. The Dystonia Group. Utility of adjunctive electromyography in botulinum toxin injection for cervical dystonia. *Movement Disorders* 2005 20(Suppl 10):P64.
72. Dystonia Study Group, **Comella CL**, et al. A direct comparison of botulinum toxin type A and type B in cervical dystonia: A multicenter, randomized, double-blind, parallel study. *Movement Disorders* 2005 20(Suppl 10):P103.
73. Zats S, Lewis SL, **Comella CL**. Hemiparkinsonism and facial dyskinesia in a patient with a contralateral mesencephalic cyst. *Movement Disorders* 2005 20(Suppl 10):P378.
74. Itin I, **Comella CL**. Restless legs syndrome. *Prim Care*. 2005 June;32(2):435-48.
75. Widnell KL, **Comella C**. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations. *Mov Disord*. 2005;20 Suppl 11:S30-7.